Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2017-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事2016年度述职报告（权玉华）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2016 Annual Work Report" from a specific independent director of the company. It details the director's attendance at board meetings, opinions expressed, investigations conducted, committee roles, and efforts to protect investor rights during the 2016 fiscal year. The content is a narrative report on the director's activities and responsibilities rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings. It is a management-related report focusing on board and director activities. Therefore, the document best fits the category of Board/Management Information (MANG). The document length is short (2119 characters), and it is a full report, not an announcement of a report, so it is not RPA or RNS.
2017-03-30 Chinese
国金证券股份有限公司关于公司2016年度保荐工作报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2016年度保荐工作报告" which translates to "2016 Annual Sponsorship Work Report" by Guojin Securities Co., Ltd. for Ruikang Pharmaceutical Co., Ltd. It details the sponsorship work overview, supervision of fundraising, company governance, internal control reviews, and other compliance and oversight activities related to the company. The content is focused on the sponsor's review and monitoring activities rather than the company's own financial results or management discussion. It is not an annual report (10-K), audit report, or earnings release. It is a specialized report related to sponsorship work, which is a regulatory and compliance function in the Chinese securities market. This type of document does not fit into the typical categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory compliance report related to sponsorship duties. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory and compliance reports that do not fit other categories. The document length is 3137 characters, which is relatively short and consistent with a report rather than an announcement. Therefore, the classification is RNS with high confidence.
2017-03-30 Chinese
独立董事关于对公司累计和当期担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of 瑞康医药股份有限公司 regarding the company's cumulative and current guarantee situation. It references regulatory notice 证监发[2005]120号 about external guarantees by listed companies and confirms compliance and absence of illegal guarantees. The document is short (677 characters) and primarily contains an independent directors' opinion and certification about guarantees, not a full audit or financial report. It is not an annual report, audit report, or financial statement. It is a regulatory compliance statement related to guarantees, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance attestation.
2017-03-30 Chinese
关于2016年度内部控制的自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2016年度内部控制的自我评价报告" which translates to "2016 Annual Internal Control Self-Evaluation Report." It is issued by the company's board and management, detailing the internal control system, its implementation, supervision, and evaluation for the fiscal year 2016. The content includes detailed descriptions of internal control objectives, principles, organizational structure, implementation, audit, information disclosure controls, related party transactions, guarantees, subsidiary management, investment controls, and identified issues with corrective plans. The document is comprehensive and contains substantive information about the company's internal control system and its effectiveness, which aligns with the scope of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a Regulatory Filing (RNS). It is not a brief announcement or a certification letter but a detailed self-evaluation report on internal controls as required by regulatory guidelines. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2016
2017-03-30 Chinese
独立董事对续聘会计师事务所的事前认可
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding their prior approval for the reappointment of an accounting firm for the 2017 audit. It references regulatory guidance from the China Securities Regulatory Commission and confirms the independent directors' agreement to rehire the auditor. The document is short (654 characters) and does not contain any financial statements or detailed audit results. It is essentially a certification or attestation related to audit engagement, not the audit report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2017-03-30 Chinese
关于公司2016年度募集资金存放与使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (verification report) regarding the "募集资金存放与使用情况" (fundraising capital deposit and usage) for the year 2016 by 瑞康医药股份有限公司. It references regulatory guidelines from the Shenzhen Stock Exchange and China Securities Regulatory Commission about the management and disclosure of raised funds. The document includes detailed audited information about the amounts raised, their deposit in special accounts, usage, and compliance with regulations. It is issued by a certified public accounting firm and includes an auditor's opinion on the fundraising capital usage report. This type of document is a standalone audit or verification report focused on the use of raised capital, not a full annual report or interim financial report. It is not a mere announcement or certification letter but contains substantive audit findings and verification results. Therefore, it fits the category of an Audit Report / Information (AR). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement. Hence, the classification is AR with high confidence. FY 2016
2017-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.